Annals of internal medicine

Cost-effectiveness of drug treatments for adults with overweight or obesity

Updated

Abstract

None of the 42 pairwise comparisons reported high certainty regarding cost-effectiveness of pharmacologic treatments for overweight or obesity.

  • Four out of 9 included studies had a low risk of bias.
  • In the 6 studies with moderate certainty, liraglutide was classified as low value compared to lifestyle modification.
  • Phentermine-topiramate and tirzepatide were considered high value when compared to lifestyle modification.
  • Semaglutide was deemed low value compared to naltrexone-bupropion and phentermine-topiramate, but high value when compared to liraglutide.
  • All studies included were model-based and had limitations in reporting and bias.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Disclosures: Disclosure forms are available with the article online.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free